Abstract & Overview
This thesis presents three notable findings: the voice of\n the patient is inconsequently incorporated in scientific research regarding\n adverse events; available instruments may be of limited value for approaching\n targeted therapy-associated mucocutaneous adverse events; and available\n knowledge about a patient-driven approach to adverse events is not broadly\n incorporated in research and clinical care.\n The voice of the patient is inconsequently incorporated in scientific\n research and the healthcare-professional plays the central role in adverse\n event diagnosis and management. The incidence of the adverse events is mainly\n measured by healthcare-professionals with suboptimal scales. As a result\n there may be underreporting of adverse events. In addition, the non-validated\n CTCAE scoring system for the grading of the adverse events is most commonly\n used while more precise grading instruments are available. Currently, most adverse\n events grading is performed by healthcare-professionals rather than by\n patients.\n The work in this thesis lead to recommendations to develop collaboration with\n patients. The conceptual co-care model of a patient-driven approach to\n adverse events of targeted agents in oncology may be complemented with a\n 3-part adverse event assessment and grading instrument, evidence based\n adverse event treatment guidelines, and obligated educational programs on the\n adverse events core competencies, and applied.